AmbioPharm (revision 14)

AmbioPharm, Inc. (trading as AMB; ambiopharm.net) is a peptide active-ingredient manufacturer and contract development organisation trading as AmbioPharm from Beijing, China, incorporated in 2003 and supplying research peptides and raw materials with batch documentation.^[1][2]

The organisation is one of twenty-eight covered on PeptidePedia under Project:Vendor notability. Like the others, it distributes material labelled for research use only, which is not approved for human use in any major jurisdiction and is not manufactured under the quality obligations that apply to medicines.^[3]

This article describes what is verifiable. Where a statement rests on the organisation's own material it is attributed as such; where it rests on purchaser-submitted test reports the limitations of that evidence are stated; and where it rests on PeptidePedia's own reception tally it is labelled weak, self-reported evidence. Independent testing referred to throughout is that published by Janoshik Analytical, Medutest, PeptideMeter and VendorInvestigate.^[4]

Incorporated in Beijing in 2003, the organisation sits with the earlier incorporation dates among the entities covered on this wiki and predates the current research-peptide market by roughly a decade.^[1] The organisation's own material describes a business built on peptide active pharmaceutical ingredient supply and contract development rather than on catalogue distribution alone.^[2]

The organisation describes itself as operating as a contract development and manufacturing organisation alongside its own listings. That is a self-published characterisation and is recorded here as one: nothing available to this wiki establishes the manufacturing arrangements behind it, and a registered business scope is a licensing fact rather than a capability finding.^[2][1]

The documentary base is the registry record, the organisation's own material and purchaser-submitted test reports. No independent coverage has been identified, which is a characteristic of the sector rather than of this entity.

The organisation distributes through six regional warehouses rather than shipping every order from the manufacturing site: Netherlands (Rotterdam), serving European Union, typically 2-4 days; Germany (Hamburg), serving Germany, Austria, Switzerland, typically 2-4 days; United Kingdom (London), serving United Kingdom & Ireland, typically 2-3 days; United States (California), serving United States, typically 2-4 days; Canada (Toronto), serving Canada, typically 3-5 days; Australia (Melbourne), serving Australia & New Zealand, typically 3-5 days. Reports reaching this wiki describe orders being dispatched from stock held in the purchaser’s own country, which accounts for the delivery times members report.

Purchaser reports describe vialled lyophilised material arriving with a batch-specific certificate naming a lot, and across the submitted set the lot string on the certificate has corresponded to the vial label.^[5] That correspondence is a minimum requirement rather than an achievement.

Two determinations distinguish the submitted set from most entities covered here. Water content by Karl Fischer titration appears on the certificates described, and the counter-ion is reported as a figure with its unit rather than named or omitted.^[5][6] Together with peptide content on a separate line from chromatographic purity, those are what let a purity percentage be read as a statement about mass. Their routine presence is the most useful documentary observation available about this organisation. Reports also describe the release as signed and dated by a named individual rather than initialled.^[5]

One operational observation recurs often enough to belong in the article, and it is not about material. Purchasers describe forward stock as thinner than for comparable entities: frequently ordered lines are held regionally and arrive inside the quoted window, while less commonly ordered lines dispatch from Beijing and add approximately one week.^[5] Purchasers who asked were told the position; none reports being told before ordering.

What the record does not establish is the physical arrangement of manufacture, whether any given catalogue line is produced in-house or contracted out, or what quality system governs it. Statements to that effect in the organisation's own material are self-published and are not corroborated here.^[2][7]

The active-ingredient listings are documented differently from the catalogue lines — a specification sheet rather than a single purity figure. Purchaser reports describe bulk enquiries as quoted by the gram with a written lead time issued before commitment.^[5] Whether production occurs at the Beijing site named in the organisation's own material is not established by any source available to this wiki, and a reader should treat the attribution as a claim until it is.^[2]

Reports on AMB material submitted to PeptidePedia between 2024 and 2026 cover the incretin analogues most heavily, with a smaller set on repair and secretagogue peptides and a handful on bulk raw material. Reported area percent figures have been high across the set, and where a report and the accompanying certificate can be compared the two have generally agreed within a few tenths of a percentage point, with the certificate figure the lower of the two in the comparisons on file.^[5]

The submitted set covers a small number of the listed compounds. A reader should not read agreement on eight lines as a finding about three hundred and fifty; the unsubmitted lines are unmeasured rather than sound.^[5]

• Certificate of analysis
• Third-party testing
• Area percent purity
• Peptide content
• Research use only